13F Holdings
中文EN

SAEN Genenta Science S.p.A. Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1838716 · Reporting currency EUR

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY26.7%
TTM EPS YoY32.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.0%
ROA-28.0%
ROIC (approx.)-43.1%
Asset turnover—

Leverage & solvency

Liabilities / assets31.5%
Debt / equity0.00x
Current ratio14.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.05x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense2.70M4.81M6.47M5.34M3.39M
SG&A expense3.90M4.95M5.26M5.71M2.30M
Operating income-6.60M-9.76M-11.73M-11.04M-5.69M
Pretax income-6.53M-8.91M-11.65M-8.48M-5.53M
Net income-6.53M-8.91M-11.65M-8.48M-5.53M
EBITDA-6.58M-9.72M-11.69M-11.04M-5.68M
EPS (basic)——-0.64-0.47-0.37
EPS (diluted)-0.33-0.49-0.64-0.47-0.37
Weighted avg. shares (diluted)19.71M18.27M18.22M18.22M15.08M
Balance sheet
Cash & equivalents5.53M4.58M3.69M29.79M37.24M
Short-term investments22.62M8.08M15.08M——
Current assets29.98M14.47M21.26M31.72M38.76M
PP&E, net22,46542,92282,977111,63923,090
Intangibles———87,000—
Total assets31.89M14.82M22.35M33.44M40.03M
Current liabilities2.12M2.10M1.74M2.18M1.14M
Total liabilities10.05M2.33M1.91M2.30M1.17M
Shareholders' equity21.84M12.50M20.43M31.14M38.86M
Shares outstanding23.43M18.29M18.22M18.22M18.22M
Cash flow statement
Operating cash flow-6.87M-6.24M-11.21M-7.42M-6.96M
Capital expenditure7,6254,46813,79127,0709,009
Free cash flow-6.88M-6.24M-11.22M-7.45M-6.97M
Investing cash flow-14.54M6.88M-14.89M-27,070-9,009
Financing cash flow22.29M270,885531—28.74M
Depreciation & amortization28,08244,52342,4536,1404,889
Stock-based compensation1.01M847,255739,884722,735497,104

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.